GDF-15 inhibitors show promise against hard-to-treat tumors in clinical trial
A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation ...
Santé log17 小时
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
UNLOXCYT (cosibelimab-ipdl) is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or ...